WCM Investment Management LLC Buys Shares of 241,894 IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

WCM Investment Management LLC acquired a new position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 241,894 shares of the company's stock, valued at approximately $6,030,000. WCM Investment Management LLC owned about 0.28% of IDEAYA Biosciences at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. abrdn plc lifted its stake in IDEAYA Biosciences by 31.7% during the fourth quarter. abrdn plc now owns 306,723 shares of the company's stock worth $7,883,000 after purchasing an additional 73,893 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in IDEAYA Biosciences by 12.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,327 shares of the company's stock worth $471,000 after buying an additional 2,078 shares during the period. R Squared Ltd acquired a new stake in IDEAYA Biosciences in the fourth quarter worth $35,000. KBC Group NV increased its position in IDEAYA Biosciences by 84.6% in the fourth quarter. KBC Group NV now owns 4,197 shares of the company's stock worth $108,000 after buying an additional 1,923 shares during the period. Finally, SG Americas Securities LLC increased its position in IDEAYA Biosciences by 444.2% in the fourth quarter. SG Americas Securities LLC now owns 18,486 shares of the company's stock worth $475,000 after buying an additional 15,089 shares during the period. 98.29% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on IDYA shares. UBS Group started coverage on IDEAYA Biosciences in a research report on Thursday, October 24th. They issued a "buy" rating and a $50.00 target price on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $61.00 target price on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Oppenheimer reaffirmed an "outperform" rating and issued a $53.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday, October 29th. Leerink Partners lowered IDEAYA Biosciences from an "outperform" rating to a "market perform" rating and dropped their target price for the stock from $41.00 to $27.00 in a research report on Tuesday, November 5th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a research report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $53.67.

IDEAYA Biosciences Trading Down 5.4 %

NASDAQ:IDYA traded down $1.19 during mid-day trading on Thursday, reaching $20.76. 1,245,177 shares of the stock were exchanged, compared to its average volume of 862,268. The business has a fifty day moving average price of $24.60 and a 200 day moving average price of $30.18. The firm has a market capitalization of $1.79 billion, a PE ratio of -8.91 and a beta of 0.82. IDEAYA Biosciences, Inc. has a 1-year low of $20.66 and a 1-year high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its earnings results on Tuesday, February 18th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.86). On average, sell-side analysts forecast that IDEAYA Biosciences, Inc. will post -2.45 earnings per share for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.